Top Stories
Yochanra (tinengotinib) has been conditionally approved for patients with FGFR2-mutated advanced cholangiocarcinoma previously treated with FGFR inhibitors.
The drugs will be delivered to eligible patients' homes for free, with same-day service available across more than 3100 US cities and towns.
The restructuring efforts are expected to result in $40 million in annualised savings.
The biotech's stock jumped 65% after selling 21.3 million shares at $18 apiece.
The German drugmaker now expects net sales for the full year to range from €21 billion to €21.8 billion, with organic growth of 1% to 3%.
Conference News
First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor supportAnalysis of blood and ...
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expecte...
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive meta...
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 millionStronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted E...
All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-172616-Week Topline Data Expected in the Fourth Quarter of 2026CAMBRIDGE, ...
